HPV-Related Malignancy
16
8
9
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
6.3%
1 terminated out of 16 trials
83.3%
-3.2% vs benchmark
6%
1 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
The Organ Transplant Recipient HPV and Skin Cancer Study
HPV in Blood Samples From Cervical Cancer Patients.
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Postpartum HPV Vaccination